CSIMarket
 


Tricida Inc   (TCDA)
Other Ticker:  
 

Tricida Inc 's Working Capital Ratio

TCDA's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2022, Working Capital Ratio deteriorated to 5.84 below Tricida Inc 's average Working Capital Ratio.

Within Major Pharmaceutical Preparations industry 255 other companies have achieved higher Working Capital Ratio than Tricida Inc in third quarter 2022. While Working Capital Ratio total ranking has improved so far during the III Quarter 2022 to 1012, from total ranking in the second quarter 2022 at 1083.

Explain Working Capital Ratio
How much in Current Assets TCDA´s has?
What is the value of TCDA´s Current Liabilities?


TCDA Working Capital Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change -38.61 % -22.42 % -41.27 % -16.89 % -48.58 %
Y / Y Current Assets Change -45.44 % -43.44 % -42.01 % -53.65 % -53.64 %
Working Capital Ratio MRQ 5.84 5.93 5.76 5.44 6.57
TCDA's Total Ranking # 1012 # 1083 # 1178 # 1138 # 1013
Seq. Current Liabilities Change -18.18 % -22.34 % -16.85 % 16.2 % 3.39 %
Seq. Current Assets Change -19.43 % -20.01 % -12.05 % -3.73 % -16.49 %



Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 256
Healthcare Sector # 459
Overall Market # 1012


Working Capital Ratio Statistics
High Average Low
16.51 8.9 5.44
(Dec 31 2018)   (Dec 31 2021)




Financial Statements
Tricida Inc 's Current Liabilities $ 14 Millions Visit TCDA's Balance sheet
Tricida Inc 's Current Assets $ 82 Millions Visit TCDA's Balance sheet
Source of TCDA's Sales Visit TCDA's Sales by Geography


Cumulative Tricida Inc 's Working Capital Ratio

TCDA's Working Capital Ratio for the trailling 12 Months

TCDA Working Capital Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth -38.61 % -22.42 % -41.27 % -16.89 % -48.58 %
Y / Y Current Assets TTM Growth -45.44 % -43.44 % -42.01 % -53.65 % -53.64 %
Working Capital Ratio TTM 5.7 5.9 6.43 6.36 7.52
Total Ranking TTM # 825 # 911 # 705 # 745 # 665
Seq. Current Liabilities TTM Growth -18.18 % -22.34 % -16.85 % 16.2 % 3.39 %
Seq. Current Assets TTM Growth -19.43 % -20.01 % -12.05 % -3.73 % -16.49 %


On the trailing twelve months basis In spite of the year on year decrease in TCDA's Current Liabilities to $14.13 millions, cumulative Working Capital Ratio to 5.7 below the TCDA average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 275 other companies have achieved higher Working Capital Ratio than Tricida Inc . While Working Capital Ratio overall ranking has improved so far to 825, from total ranking during the twelve months ending second quarter 2022 at 911.

Explain Working Capital Ratio
How much in Current Assets TCDA´s has?
What is the value of TCDA´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 276
Healthcare Sector # 482
Within the Market # 825


trailing twelve months Working Capital Ratio Statistics
High Average Low
13.14 8.23 5.01
(Sep 30 2019)   (Sep 30 2022)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2022 MRQ Current AssetsSep 30 2022 MRQ Current Liabilities
Fulcrum Therapeutics Inc   15.49 $ 227.727  Millions$ 14.699  Millions
Crinetics Pharmaceuticals Inc   15.41 $ 378.422  Millions$ 24.556  Millions
Pds Biotechnology Corp  15.37 $ 74.411  Millions$ 4.841  Millions
Nkarta Inc   15.17 $ 400.918  Millions$ 26.425  Millions
Akero Therapeutics Inc   14.97 $ 377.946  Millions$ 25.243  Millions
Oric Pharmaceuticals Inc   14.96 $ 198.685  Millions$ 13.284  Millions
Protagenic Therapeutics Inc new  14.91 $ 8.254  Millions$ 0.554  Millions
Anixa Biosciences Inc   14.83 $ 30.200  Millions$ 2.037  Millions
Lianbio  14.72 $ 324.238  Millions$ 22.027  Millions
Xoma Corporation  14.70 $ 79.741  Millions$ 5.425  Millions
Sage Therapeutics Inc   14.70 $ 1,465.104  Millions$ 99.687  Millions
Kalvista Pharmaceuticals Inc   14.69 $ 151.216  Millions$ 10.294  Millions
Cytokinetics Incorporated  14.63 $ 884.275  Millions$ 60.440  Millions
Lumos Pharma Inc   14.38 $ 78.832  Millions$ 5.483  Millions
Verrica Pharmaceuticals Inc   14.10 $ 43.395  Millions$ 3.078  Millions
Rani Therapeutics Holdings Inc   14.02 $ 100.720  Millions$ 7.186  Millions
Pliant Therapeutics Inc   13.99 $ 365.965  Millions$ 26.161  Millions
Sensei Biotherapeutics Inc   13.95 $ 118.482  Millions$ 8.492  Millions
Histogen Inc   13.93 $ 16.338  Millions$ 1.173  Millions
Liquidia Corporation  13.81 $ 103.058  Millions$ 7.460  Millions
Annexon Inc   13.59 $ 274.777  Millions$ 20.220  Millions
Larimar Therapeutics Inc   13.50 $ 127.127  Millions$ 9.420  Millions
Aclaris Therapeutics Inc   13.49 $ 256.573  Millions$ 19.023  Millions
Xenetic Biosciences Inc   13.48 $ 14.167  Millions$ 1.051  Millions
Iveric Bio Inc   13.40 $ 329.478  Millions$ 24.588  Millions
Arcutis Biotherapeutics Inc   13.39 $ 496.719  Millions$ 37.102  Millions
Erasca Inc   13.21 $ 365.751  Millions$ 27.679  Millions
Kronos Bio Inc   13.16 $ 264.630  Millions$ 20.105  Millions
Pepgen Inc   13.16 $ 204.248  Millions$ 15.519  Millions
Calcimedica Inc   13.03 $ 45.071  Millions$ 3.460  Millions

Date modified: 2023-03-23T16:24:08+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com